The DOI matches its Crossref record.
A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia [letter]
Abstract
Several characteristics have been predictive of outcome of therapy for relapsed or "primary refractory" acute myelogenous leukemia (AML).'-4Among these are duration of first complete remission (CR) and the number of, and response to, prior salvage regimens.Using these covariates, we have developed a system that stratifies patients by probability of response to previous salvage agents.This system may be useful when comparing new salvage regimens and when considering which patients might be candidates for phase I studies.The system is based on analysis of outcome (CR or not) in 206 patients (median age, 56 years) who received chemotherapy without transplantation for relapsed or primary refractory AML, excluding acute promyelocytic leukemia (APL), at M.D. Anderson between 1991 and 1994.For first salvage, 68% of the patients received conventional regimens (principally high-dose ara-C-based), and the remaining 32% received investigational regimens (usually single agents such as topotecan, 2 CDA, CI 973, or taxol).The overall CR rate was 23%.Ninety-three of the 206 patients received a second salvage attempt either at second relapse or after failing to respond to the first attempt.Forty-three percent of the 93 received conventional and 57% received investigational regimens; the overall CR rate was 1 I %.Forty patients received a third and 17 patients received a fourth salvage regimen, with CR rates of 10% and 6%, respectively.The system recognizes four groups: (1) patients with an initial CR duration in excess of 2 years who are receiving their first salvage attempt (15 patients; CR rate, 73%; 95% confidence interval [CI], 45% to 92%); (2) patients with an initial CR duration of 1 to 2 years who are receiving their first salvage attempt (30 patients; CR rate, 47%; 95% CI, 28% to 66%); (3) patients with a first CR lasting less than 1 year, or with no initial CR, who are receiving their initial salvage attempt (160 patients; CR rate, 14%; 95% CI, 8% to 21%); and (4) patients with an initial CR under 1 year, or with no initial CR, who are receiving a second or subsequent (up to and including a fourth) salvage regimen, having not responded to a first salvage attempt (58 patients; 96 salvage attempts; CR rate, 0%; 95% CI, 0% to 4%).Other patients, eg, those who responded on a first salvage attempt and who proceed to a second salvage regimen, are excluded from consideration because of small numbers, although there are suggestions that patients who respond to the first regimen may be relatively responsive to the second (3/7 CRs if first CR duration was I to 2 years; 2/13 if it was shorter).The system was similarly effective in stratifying the 137 patients who received both initial and salvage therapy at M.D. Anderson and the 69 patients who were referred in relapse (49% of whom had received 2 1 regimen for relapse before referral), with CR rates of 8 of 1 I , 1 1 of 24, 11 of 102, and 0 of 80, and 3 of 4, 3 of 6 , 12 of 58, and 0 of 18 for the 4 groups in the M.D. Anderson and referred categories, respectively.Considering only patients who received conventional (eg, HDAC,
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Estey, E., & Döhner, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69780-8 · Cited by 1,296
Self-citationPrognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse
Breems, D. A., Van Putten, W. L. J., Huijgens, P. C., Ossenkoppele, G. J., Verhoef, G. E. G., Verdonck, L. F., Vellenga, E., De Greef, G. E., Jacky, E., Van der Lelie, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.027 · Cited by 511
Uy, G. L., Rettig, M. P., Motabi, I. H., McFarland, K., Trinkaus, K. M., Hladnik, L. M., Kulkarni, S., Abboud, C. N., Cashen, A. F., Stockerl-Goldstein, K. E., et al. (2012) · Blood · doi:10.1182/blood-2011-10-383406 · Cited by 400
Perna, F., Berman, S. H., Soni, R. K., Mansilla-Soto, J., Eyquem, J., Hamieh, M., Hendrickson, R. C., Brennan, C. W., & Sadelain, M. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.004 · Cited by 346
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Uy, G. L., Aldoss, I., Foster, M. C., Sayre, P. H., Wieduwilt, M. J., Advani, A. S., Godwin, J. E., Arellano, M. L., Sweet, K. L., Emadi, A., et al. (2021) · Blood · doi:10.1182/blood.2020007732 · Cited by 326
Metadata
- Authors
- Estey, E., Kornblau, S., Pierce, S., Kantarjian, H., Beran, M., & Keating, M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1996-07-15
- Volume
- 88
- Issue
- 2
- Pages
- 756-756
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2466569700
- Cited by
- 109
- References
- 0
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia [letter]. https://app.cochat.ai/papers/10.1182/blood.v88.2.756.bloodjournal882756
- The paper
- Estey, E., Kornblau, S., Pierce, S., Kantarjian, H., Beran, M., & Keating, M. (1996). A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia [letter]. Blood. https://doi.org/10.1182/blood.v88.2.756.bloodjournal882756
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.